BACKGROUND: We used a real-time reverse transcriptase polymerase chain reaction (RT-PCR) method for quantification of each alpha(1)-adrenoceptor (alpha(1)-AR) subtype expression level, and examined whether age and prostate volume influence human prostate alpha(1)-AR subtype expression. METHODS: Enrolled in our study were 75 men with lower urinary tract symptoms (LUTS) secondary to untreated benign prostatic hyperplasia (BPH). Real-time RT-PCR was performed using prostate biopsy specimens to quantify the expression level of each alpha(1)-AR subtype. RESULTS: The median expression level (interquartile range) was 1.24 (0.66-2.32), 0.16 (0.10-0.33), and 1.11 (0.75-2.27) x 1,000 copies/beta-actin for alpha(1a)-, alpha(1b)-, and alpha(1d)-AR mRNA, respectively. The expression levels differed with the individual. The expression levels of alpha(1a)-AR, alpha(1d)-AR, and total alpha(1)-AR mRNA showed a significant positive correlation with patient age, but did not correlate with prostate volume. CONCLUSION: The difference in the expression of the alpha(1)-AR subtype with the patient may be the cause of the difference in the effectiveness of several subtype-selective alpha(1)-AR antagonists from patient to patient. The increase of alpha(1)-AR mRNA expression level with age could be an important factor in the pathogenesis of clinically significant BPH.
BACKGROUND: We used a real-time reverse transcriptase polymerase chain reaction (RT-PCR) method for quantification of each alpha(1)-adrenoceptor (alpha(1)-AR) subtype expression level, and examined whether age and prostate volume influence human prostate alpha(1)-AR subtype expression. METHODS: Enrolled in our study were 75 men with lower urinary tract symptoms (LUTS) secondary to untreated benign prostatic hyperplasia (BPH). Real-time RT-PCR was performed using prostate biopsy specimens to quantify the expression level of each alpha(1)-AR subtype. RESULTS: The median expression level (interquartile range) was 1.24 (0.66-2.32), 0.16 (0.10-0.33), and 1.11 (0.75-2.27) x 1,000 copies/beta-actin for alpha(1a)-, alpha(1b)-, and alpha(1d)-AR mRNA, respectively. The expression levels differed with the individual. The expression levels of alpha(1a)-AR, alpha(1d)-AR, and total alpha(1)-AR mRNA showed a significant positive correlation with patient age, but did not correlate with prostate volume. CONCLUSION: The difference in the expression of the alpha(1)-AR subtype with the patient may be the cause of the difference in the effectiveness of several subtype-selective alpha(1)-AR antagonists from patient to patient. The increase of alpha(1)-AR mRNA expression level with age could be an important factor in the pathogenesis of clinically significant BPH.
Authors: John S Lyssand; Jennifer L Whiting; Kyung-Soon Lee; Ryan Kastl; Jennifer L Wacker; Michael R Bruchas; Mayumi Miyatake; Lorene K Langeberg; Charles Chavkin; John D Scott; Richard G Gardner; Marvin E Adams; Chris Hague Journal: Proc Natl Acad Sci U S A Date: 2010-11-29 Impact factor: 11.205
Authors: John S Lyssand; Kyung-Soon Lee; Mia DeFino; Marvin E Adams; Chris Hague Journal: Biochem Biophys Res Commun Date: 2011-08-09 Impact factor: 3.575
Authors: Brian C Jensen; Philip M Swigart; Marie-Eve Laden; Teresa DeMarco; Charles Hoopes; Paul C Simpson Journal: J Am Coll Cardiol Date: 2009-09-22 Impact factor: 24.094
Authors: Lambertus P W Witte; Christine A Teitsma; Jean J M C H de la Rosette; Martin C Michel Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 2013-11-06 Impact factor: 3.000